Colonoscopy CPT Codes 45378-45385: How to Bill Screening vs Diagnostic

Colonoscopy billing breaks into two worlds: the CPT 4537x diagnostic family (used by commercial payers and by Medicare once a screening becomes diagnostic) and the Medicare HCPCS screening codes G0105 and G0121. Picking the wrong base code is the root cause of most colonoscopy denials and patient-billing complaints.

The single most important rule: one colonoscopy = one base code. You bill the single CPT that describes the most extensive intervention performed, not a stack of them. If you remove two polyps by snare and biopsy a third lesion, you do not bill 45385 + 45385 + 45380 across all three; you follow the per-lesion / per-technique rules below. The code you report is driven by technique, not by how many lesions — and that distinction is where coders lose money.

45384 vs 45385 — the technique distinction that gets coded wrong. 45384 describes removal by hot biopsy forceps; 45385 describes removal by snare technique. Older billing guidance (including earlier versions of this page) described 45384 as "hot biopsy forceps or bipolar cautery snare." That wording came from a superseded descriptor and it is why cautery-snare cases get coded to 45384 instead of 45385 — checked against AAPC's public CPT entry for 45384 on 17 September 2026. The AMA publishes and licenses CPT, so confirm the current long descriptors in your own codebook. Either way the operative note must state the removal technique: "polyp removed" is not codeable, because the coder cannot tell forceps from snare.

When multiple techniques are used on different lesions, more than one base code may be reportable. Medicare's own instruction is narrow and worth quoting the shape of: the National Correct Coding Initiative edit pairing 45385 (column one) with 45380 (column two) may be bypassed with modifier 59 or XS when the two procedures are performed on separate lesions, and with 59 or XE when they are performed at separate patient encounters (2026 NCCI Policy Manual, Chapter VI, Section H, revision date 1 January 2026, read 17 September 2026). "Separate lesion" is the whole test — the lesions must be distinct and separately documented by site. See the Common Denials section for what happens when they are not.

Whether a colonoscopy is screening or diagnostic determines the code, the modifier, the patient's cost-share, and the frequency rules. Getting this wrong is the most common reason a GI practice gets a patient complaint and a clawback in the same month.

Screening colonoscopy = the patient is asymptomatic and the procedure is performed for colorectal cancer prevention. There is no GI symptom, no prior abnormal finding driving this visit, and the indication on the order is preventive (e.g., "screening colonoscopy, average risk"). Under section 2713 of the Public Health Service Act, a screening colonoscopy recommended by the U.S. Preventive Services Task Force is covered with no patient cost sharing by non-grandfathered commercial plans; Medicare waives both deductible and coinsurance for its screening colonoscopy codes (Medicare Claims Processing Manual, Chapter 18, §60.1.1, read 17 September 2026).

Diagnostic colonoscopy = the patient has a sign, symptom, or prior finding that prompts the exam — rectal bleeding, anemia, abdominal pain, or surveillance after prior polyps. A diagnostic colonoscopy is not a preventive service; normal cost sharing (deductible, coinsurance) applies.

A positive stool-based test no longer makes the colonoscopy diagnostic, and this trips up practices working from older guidance. For non-grandfathered commercial plans, the tri-agency guidance is explicit: a plan must cover, without cost sharing, a colonoscopy performed after a positive non-invasive stool-based or direct-visualization screening test, because the follow-up colonoscopy is an integral part of the screening — required for plan years beginning on or after 31 May 2022 (FAQs About Affordable Care Act Implementation Part 51, Q7–Q8, read 17 September 2026). Medicare made the same move from dates of service on or after 1 January 2023: the follow-on screening colonoscopy is itself a colorectal cancer screening test, is identified with the KX modifier, and is exempt from both cost sharing and the frequency limits (Chapter 18, §60.1.1 and §60.2; see 42 CFR 410.37(k), which from 1 January 2025 also covers a follow-on colonoscopy after a positive blood-based biomarker test).

The trap lives in the middle. A patient scheduled for a screening (average risk, asymptomatic, expecting $0) has a polyp found and removed during the same procedure. The intent was screening, but an intervention occurred, so the procedure code changes from a screening base to a therapeutic CPT (45380/45384/45385). Without the right modifier, the claim now looks 100% diagnostic and the payer applies cost-sharing — billing the patient money they were explicitly told they would not owe.

Medicare frequency limits — count the months the way the regulation counts them. 42 CFR 410.37(g) does not say "once every ten years"; it says payment may be made for a screening colonoscopy on a patient not at high risk after at least 119 months have passed following the month of the last screening colonoscopy, or after at least 47 months have passed following the month of the last screening flexible sigmoidoscopy. For a patient at high risk, the interval is at least 23 months since the last screening colonoscopy. Those one-month differences are real: a claim submitted on the 120th-month anniversary is fine, and a practice that tracks "ten years" to the day will hold claims a month longer than it has to — or bill them a month early. The frequency limits do not apply at all to a follow-on screening colonoscopy after a positive stool-based test billed with KX.

Who counts as high risk is also defined by regulation, not by clinical judgment: a close relative (sibling, parent or child) with colorectal cancer or an adenomatous polyp; a family history of familial adenomatous polyposis; a family history of hereditary nonpolyposis colorectal cancer; a personal history of adenomatous polyps; a personal history of colorectal cancer; or inflammatory bowel disease, including Crohn's disease and ulcerative colitis (42 CFR 410.37(a)(3)).

A screening code billed inside the frequency window is denied; verify the last screening date during eligibility, not after the denial.

Two modifiers protect the patient's $0 cost-share when a screening turns diagnostic. They are not interchangeable — using the wrong one for the payer is the difference between a clean claim and a clawback.

Modifier PT — colorectal cancer screening test, converted to diagnostic test or other procedure. This is the Medicare modifier. Append PT to the therapeutic CPT (45380, 45384, 45385) when a screening colonoscopy becomes diagnostic; Medicare's instruction is to bill the appropriate diagnostic or therapeutic code with PT rather than G0105/G0121 (Medicare Claims Processing Manual, Chapter 18, read 17 September 2026).

The coinsurance is reduced, not waived — and the percentage changes by year. Section 122 of the Consolidated Appropriations Act, 2021 phased it down. When PT is appended to at least one code on the claim to show that a screening became diagnostic or therapeutic, Medicare contractors waive the deductible and apply a reduced coinsurance of 15% for dates of service in calendar years 2023 through 2026, 10% for 2027 through 2029, and zero from 1 January 2030 (Chapter 18, §60.1.1; see also CMS Transmittal 11146). Telling a Medicare patient that a converted screening costs them nothing is wrong until 2030. Telling them it costs the standard 20% has been wrong since 2023, when the reduced rate dropped below it.

Modifier 33 — preventive services. This is the modifier for non-grandfathered commercial plans. Append 33 to the therapeutic CPT when a screening colonoscopy on such a plan becomes diagnostic. The substantive rule behind it is the tri-agency guidance: polyp removal is an integral part of a colonoscopy, so a plan may not impose cost sharing on the polyp removal during a colonoscopy performed as a screening (ACA Implementation FAQs Set 12, Q5, read 17 September 2026).

Do not read the two modifiers as strictly payer-exclusive. Medicare also recognises modifier 33 in a defined circumstance: moderate sedation furnished in support of a screening colonoscopy is reported with 33 and both deductible and coinsurance are waived, and when that screening converts, the sedation code carries PT instead and only the deductible is waived (Chapter 18, §60.1.1). PT is the converted-screening modifier; 33 is the preventive-service modifier; which one a given payer wants on a given line is a companion-guide question.

Diagnosis sequencing follows the coding guidelines, and it supports the modifier. The ICD-10-CM Official Guidelines state that a screening code may be the first-listed code when the reason for the visit is specifically the screening exam, and that a condition discovered during the screening may be assigned as an additional diagnosis (FY 2027 ICD-10-CM Official Guidelines, Section I.C.21.c.5, in force from 1 October 2026 and worded the same as in FY 2026; read 2 October 2026). So on a screening that converted, Z12.11 (encounter for screening for malignant neoplasm of colon) is first-listed and the polyp finding (for example D12.x) follows it. Medicare's own article on converted screenings likewise instructs the practice to report a screening diagnosis, giving Z12.11 and Z80.0 (family history of malignant neoplasm of digestive organs) as examples. Payers differ in how much weight they put on sequence, so treat the order as the coding guideline requires it and the modifier as the substantive signal.

Grandfathered plans are the exception, and so are plans outside the mandate. Grandfathered (pre-Affordable Care Act) plans are not bound by the section 2713 preventive requirement and may apply cost sharing even with modifier 33; short-term and excepted-benefit coverage is outside it too. Verify plan type at eligibility so the patient's financial expectation is set correctly before the procedure, not after.

This is the scenario that generates the angry phone call. Walk it line by line so your front end and your billers prevent it.

1. The order says screening. A 58-year-old, average risk, no symptoms, is scheduled for a screening colonoscopy. The scheduler and the financial counselor tell the patient: "This is preventive — you owe $0." That promise is on the record.
2. A polyp is found and removed. During the otherwise-screening exam, the GI snares a 6 mm sigmoid polyp. Clinically correct. But the procedure is now therapeutic, so the codeable CPT is 45385, not 45378 / G0121.
3. The biller drops 45385 with no modifier. The claim now reads as a straight diagnostic polypectomy. The payer applies the deductible and coinsurance — the patient gets a bill for several hundred dollars they were promised they would not owe.
4. The patient complains; the practice eats it. Facing a documented promise of $0, most practices write off the balance rather than fight it. The leakage scales with how often screenings find something, which is a clinical question your own pathology log answers better than any published average — pull the share of your screening colonoscopies that converted last quarter and multiply by the cost share you wrote off.

The fix is two fields, captured before the claim drops:

• Modifier PT (Medicare) or 33 (non-grandfathered commercial) on the therapeutic CPT.
• Z12.11 sequenced first as the primary diagnosis, with the polyp finding secondary.

When both are present, the payer can recognise the encounter as a screening that converted: no cost sharing on a non-grandfathered commercial plan, and on Medicare the deductible waived with the reduced coinsurance for the year of service (15% through 2026). The operative note must state the intent was screening. If the GI dictates "diagnostic colonoscopy for evaluation of..." the documentation contradicts the modifier and the appeal fails. Intent has to be screening in the chart, the order, and the diagnosis sequence for the modifier to hold up under audit.

Colonoscopy reimbursement has two components — the professional (physician) fee and, in a facility (ASC or hospital outpatient), a separate facility fee. The dollars below are directional; the exact allowable depends on the year's CMS Physician Fee Schedule (PFS), the place of service, and your contracted commercial rates, which vary by payer and region — verify your fee schedule rather than relying on a single national number.

RVU/PFS basis. The 4537x family is valued by RVUs and the therapeutic codes carry more work than the diagnostic base code. We do not publish dollar figures for them: the allowable depends on the year's conversion factor, your locality's geographic adjustment, the place of service and — for commercial payers — a contract we have not seen. Pull the national payment amount for each code from the CMS Physician Fee Schedule relative value files and apply your own locality and contract. Do not bill off a number from a blog, including this one.

The bundling rules that cause CO-97 / CO-236 denials:

• One base code per session. The 2026 NCCI Policy Manual, Chapter VI states it twice over: surgical endoscopy includes diagnostic endoscopy, so a diagnostic endoscopy code is not reported with a surgical endoscopy code; and where multiple endoscopic services are performed, the most comprehensive code describing what was done is the one reported. Billing 45378 (the diagnostic look) alongside 45385 (the polypectomy) fails on both counts.
• 45380 bundles into 45385 for the same lesion. Biopsy of a lesion you then snare-remove is included in 45385. Billing both for the same lesion hits the NCCI procedure-to-procedure edit that posts as CO-236. The manual's own bypass condition is narrow: modifier 59 or XS when the two procedures were performed on separate lesions, 59 or XE when they were performed at separate patient encounters.
• Multiple polyps, same technique = one code. NCCI Chapter VI puts it as a general endoscopy rule: when the same endoscopic procedure is performed multiple times at a single patient encounter in the same region as defined by the CPT codebook narrative, only one code may be reported, with one unit of service. Removing four polyps all by snare is one unit of 45385, not four. NCCI also publishes a Medically Unlikely Edit — a maximum units value per code per day — for practitioner services; check the current table rather than assuming a number.
• Bowel prep, moderate sedation, and the screening look are inherent to the procedure and are not separately billable on top of the colonoscopy CPT.

Incomplete colonoscopy — what Medicare actually instructs, and where it differs by setting. When a covered colonoscopy is attempted but cannot be completed because of extenuating circumstances, Medicare pays for the interrupted procedure. On the professional claim, suffix the colonoscopy code with modifier 53 (the fee schedule carries specific values for 44388-53, 45378-53, G0105-53 and G0121-53) and payment is calculated using one-half the value of the inputs. On the ASC or facility claim, use modifier 73 or 74 as appropriate. This applies to both screening and diagnostic colonoscopies, and the frequency clock is not consumed — when the colonoscopy is next attempted and completed, it is paid normally (Medicare Claims Processing Manual, Chapter 18, §60.2, read 17 September 2026).

The CPT codebook addresses incomplete colonoscopies in its own surgery guidelines, and its instruction is not identical to Medicare's; because the AMA licenses that text rather than publishing it, we are not paraphrasing it here. Read the incomplete-colonoscopy paragraph in your current codebook and your MAC's or payer's article before you choose between 52 and 53 on a therapeutic code. Either way, document the exact point the scope reached and the clinical reason, so the reduced payment is supportable on audit.

Every codeable element below should be in the operative report before the claim is built. Missing any one of them is the most common root cause of a downcode, a denial, or a clawback on audit.

• Indication and intent. Screening (asymptomatic, preventive) vs diagnostic (symptom or prior finding) — stated explicitly. "Screening colonoscopy, average risk" vs "colonoscopy for rectal bleeding." This drives screening vs diagnostic coding and the modifier.
• Risk level (for Medicare screening). Not high risk (G0121) versus high risk (G0105), with the qualifying history documented against the regulatory list — close relative with colorectal cancer or an adenomatous polyp, family history of familial adenomatous polyposis or of hereditary nonpolyposis colorectal cancer, personal history of adenomatous polyps or of colorectal cancer, or inflammatory bowel disease.
• Extent of exam. Cecum reached and identified by landmark (appendiceal orifice, ileocecal valve) — or, if not, the most proximal extent reached (drives modifier 52/53).
• Removal technique, per lesion. Snare technique (45385), hot biopsy forceps (45384), biopsy (45380). "Polypectomy" with no technique is not codeable — the GI must name the tool.
• Lesion sites and count. Location of each lesion (cecum, ascending, transverse, descending, sigmoid, rectum) to support separate-lesion reporting with modifier 59/XS when more than one technique is used.
• Conversion documentation. If a screening became diagnostic, the note must state the exam began as a screening and that a finding prompted the intervention — the basis for modifier PT or 33 and for first-listing Z12.11.
• The trigger, when the exam followed a positive stool-based test. Document the prior positive test and its date. On Medicare that supports the KX modifier and exempts the claim from the frequency limits; on a non-grandfathered commercial plan it is why the exam is a screening rather than a diagnostic study.
• Pathology linkage. The specimen(s) sent to the lab — a separate claim that runs through laboratory and pathology billing — and, on the post-pathology claim, the confirmed diagnosis (e.g., D12.5 sigmoid polyp) to support medical necessity and surveillance interval coding.

If your GI procedure notes routinely say only "polyp removed," the highest-ROI fix is a one-line dictation prompt forcing technique + site + intent. It eliminates the 45384/45385 swap, supports the conversion modifier, and survives audit.

Colonoscopy claims fail on a predictable short list of CARC codes. Here is the decoder and the fix for each.

CARC meanings above are paraphrased from the X12 Claim Adjustment Reason Code list, read 17 September 2026; X12 licenses the official text, so read each code as your own remittance prints it. Note what is not in the table: there is no CARC that means "you wrongly billed a screening patient." The money simply moves to a PR line, the patient calls, and the practice writes it off — which is why this failure never shows up in a denial-rate report.

The two problems that cost GI practices the most are the bundling edits (CO-97/CO-236) and the screening cost-share trap. Bundling denials are a coding-discipline problem — one base code per technique, modifier 59/XS only for genuinely separate, documented lesions. The cost-share trap is a front-end and modifier problem — set the patient's expectation at eligibility, then protect it with PT or 33 and the correct first-listed diagnosis. For the full named-code library, see our CARC denial codes list; for the modifier-59-vs-X-modifier decision that drives separate-lesion reporting, see our modifier 59 vs X-modifiers guide. If denials are stacking up, outsourced denial management services can categorize the colonoscopy denial worklist by root cause and run the appeals.

A GI or gastroenterology billing operation that runs clean on colonoscopy claims does five things consistently:

1. Eligibility checks the last screening date and the plan type before the procedure, so frequency denials and grandfathered-plan surprises never reach the patient. The financial counsellor sets the cost-share expectation accurately — including the "if we find and remove a polyp, here is what changes" conversation, which for a Medicare patient in 2026 means the deductible is waived and 15% coinsurance applies, and for a non-grandfathered commercial plan means nothing changes.
2. Procedure notes are templated to force technique + site + intent. No "polyp removed" without the tool named; no diagnostic colonoscopy without the symptom; no screening without the risk level. This single fix kills the 45384/45385 swap and supports every conversion modifier.
3. The screening-turned-diagnostic workflow is automatic. When a screening converts, the claim build appends PT (Medicare) or 33 (non-grandfathered commercial) and first-lists Z12.11 — every time, not by memory. When the exam followed a positive stool-based test, the Medicare claim carries KX. This is the highest-leverage control in colonoscopy billing.
4. One base code per technique is enforced at scrub. NCCI PTP edits catch 45378+45385 and same-lesion 45380+45385 before submission; the MUE catches inflated units on 45385. Separate-lesion claims carry modifier 59/XS with the documentation attached.
5. The colonoscopy denial worklist is categorized by CARC root cause — bundling (97/236), screening/frequency (49/119), medical necessity (50), and cost-share trap — so the team fixes the cause, not the symptom, and the same denial does not recur next quarter.

These five disciplines protect both the diagnostic-versus-screening revenue split and the patient cost-share promise — the two places colonoscopy billing leaks money. If your team does not have the bandwidth to run NCCI scrubbing, conversion-modifier logic and the denial-categorisation loop, an outsourced partner can own them end to end. What none of it can do is change a coverage answer: where the plan excludes the service or the interval has not elapsed, the right outcome is an accurate patient conversation before the procedure, not a better appeal after it.